GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Clinical Bite Force Study of Two Marketed Adhesives Against no Adhesive
Not Applicable
Completed
- Conditions
- Denture Retention
- Interventions
- Other: Negative ControlOther: Test ProductOther: Positive Contol
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 44
- Registration Number
- NCT03037307
- Locations
- 🇺🇸
GSK Investigational Site, Indianapolis, Indiana, United States
Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 614
- Registration Number
- NCT03034967
- Locations
- 🇪🇸
GSK Investigational Site, Zaragoza, Spain
A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: UMEC/VI 62.5/25 mcg via ELLIPTADrug: UMEC 62.5 mcg via ELLIPTADrug: Placebo via DISKUSDrug: Placebo via ELLIPTA
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2696
- Registration Number
- NCT03034915
- Locations
- 🇸🇪
GSK Investigational Site, Örebro, Sweden
Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)Drug: Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT03031496
- Locations
- 🇿🇦
GSK Investigational Site, Bloemfontein, South Africa
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 105
- Registration Number
- NCT03029247
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
Phase 3
Completed
- Conditions
- Anaemia
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 312
- Registration Number
- NCT03029208
- Locations
- 🇬🇧
GSK Investigational Site, Middlesbrough, United Kingdom
Long Term Special Drug Use Investigation of Mepolizumab
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1000
- Registration Number
- NCT03028480
Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: GSK3196165 Dose 1Drug: GSK3196165 Dose 2Drug: GSK3196165 Dose 3Drug: Placebo
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT03028467
- Locations
- 🇯🇵
GSK Investigational Site, Wakayama, Japan
A Cross-sectional Study on COPD Prevalence
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Procedure: Medical testsOther: Questionnaire
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9362
- Registration Number
- NCT03028207
- Locations
- 🇪🇸
GSK Investigational Site, Zaragoza, Spain
Study of Mepolizumab Safety Syringe in Asthmatics
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT03021304
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
© Copyright 2025. All Rights Reserved by MedPath